



Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

January 4, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2022-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference.

A webcast of this presentation will be available on the "Investors & News" section of the company's website, www.axcellatx.com, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Axcella's website for 90 days following the event.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company's website in the "Investors & News" section. Accordingly, investors should monitor this portion of the company's website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company's product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella's pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company's unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220103005465/en/): <https://www.businesswire.com/news/home/20220103005465/en/>

Jason Fredette
jfredette@axcellatx.com
(857) 320-2236

Source: Axcella Therapeutics